Mike Biology: The revenue contribution of AD testing reagents is currently not significant.

Recently, Mike Biotech stated at an analyst conference that the revenue contribution from its AD test reagents is currently minimal. The company has obtained three registrations in this field, which is mainly still in the market promotion phase. It is expected that the company will obtain all registrations in this area next year, and it believes that the market potential for future AD products is promising. The testing products themselves are gaining attention as drugs enter the market, but currently, there are relatively few manufacturers in the industry that can conduct testing and hold registrations. Among them, Roche mainly focuses on cerebrospinal fluid testing, while the company is conducting blood-based AD testing, which is still in the educational phase of the market.